TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03328832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
Study: NCT03159910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shoulder-Café
Description: Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder-Guidance
Description: Home-based shoulder exercise and written counselling.
Study: NCT02025374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine % 0.5
Study: NCT04326218

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing
Study: NCT02785692

Intervention type: RADIATION
Intervention: Radiation
Description: preoperative Radiotherapy/ IMRT
Study: NCT01630317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral line
Description: Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Central line vein
Description: Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
Study: NCT01637896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB+BMS
Description: drug-eluting balloon predilation and bare metal stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA+DES
Description: conventional balloon predilation and drug-eluting stent implantation
Study: NCT02012218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Study: NCT03186625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Panax Notoginseng Granule
Description: Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Granule
Description: Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Study: NCT04067492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH - 104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren®
Description: Enteric-coated tablets, 25 mg and 50 mg
Study: NCT02560090

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Surveys
Description: The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic Nurse Intervention
Description: A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Community Health Worker
Description: An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
Study: NCT03704038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP level
Description: Patients will have variable PEEP levels and will be monitored

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP level
Description: Patients will have variable PEEP levels and will be monitored

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP level
Description: Patients will have variable PEEP levels and will be monitored
Study: NCT04042454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk based anti-regurgitation infant formula
Description: Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
Study: NCT02706119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous glargine insulin
Description: Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
Study: NCT04042454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based infant formula
Description: Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
Study: NCT04180098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-mill intervention
Description: A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: C-mill intervention
Description: A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Participants in the control group are placed on a waiting list.
Study: NCT03020004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir (DNV) 100mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: PegIFN subcutaneous injection at 180 mcg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
Study: NCT05011175

Intervention type: OTHER
Intervention: Survey
Description: Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
Study: NCT03374735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SETALUM™ Sealant
Description: SETALUM™ Sealant to be applied on the suture line
Study: NCT05576324

Intervention type: DRUG
Intervention: Elexacaftor / Ivacaftor / Tezacaftor
Description: Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.

Intervention type: DRUG
Intervention: Elexacaftor / Ivacaftor / Tezacaftor
Description: Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
Study: NCT01714323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Care
Description: A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
Study: NCT00407602

Intervention type: DEVICE
Group type: OTHER
Intervention: Implant of Argus II Retinal Prosthesis
Description: epiretinal implantation of device
Study: NCT03954548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CB-17-08 CADe
Description: CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
Study: NCT01490216

Intervention type: DRUG
Group type: OTHER
Intervention: lisdexamfetamine
Description: 20mg q.d. to 70mg b.i.d
Study: NCT05561647

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study: NCT02706119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin added to TPN bag
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin added to TPN bag
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Study: NCT04174859

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment dose is following the description of physicians.
Study: NCT01202240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib (CP-690,55) plus Ketoconazole
Description: Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
Study: NCT04162470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3918
Description: Subcutaneous (SC) every week (QW) over the treatment period
Study: NCT03541499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
Study: NCT04210492

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 Gray (Gy) regimen
Description: Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
Study: NCT02245867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Description: The antibody binds to the pathologic material and initiates a neutrophil/macrophage response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Description: The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
Study: NCT00091962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation; Treatment recommendations
Description: Counseling program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Recommendations to patients' PCP for medication to treat depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Physicians' Usual care
Study: NCT01102920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural strategies to promote physical activity and weight loss
Description: 8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP-treatment as usual (during nights)
Study: NCT02333812

Intervention type: OTHER
Intervention: Stroboscopic nasopharyngeal laryngoscopy

Intervention type: OTHER
Intervention: Stroboscopic nasopharyngeal laryngoscopy

Intervention type: OTHER
Intervention: Stroboscopic nasopharyngeal laryngoscopy
Study: NCT02360852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: A4250 once daily
Study: NCT01409824

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CDSS
Description: Clinical Decision Support System
Study: NCT01697059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin + Amoxicillin
Study: NCT02820441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01544348

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 5 mg Subcutaneous
Description: A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 15 mg Subcutaneous
Description: A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 60 mg Subcutaneous
Description: A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 150 mg Subcutaneous
Description: A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 300 mg Subcutaneous
Description: A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 300 mg Intravenous
Description: A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
Study: NCT02294617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Subject will use electronic cigarette for 3 days.
Study: NCT00659841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01229241

Intervention type: DRUG
Group type: OTHER
Intervention: local anesthetic
Description: postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml

Intervention type: DRUG
Group type: OTHER
Intervention: local anesthetic
Description: postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml
Study: NCT03689868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality headset with calming scenery
Study: NCT00617838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal gluten introduction
Description: Optimization of gluten introduction by nutritional counselling
Study: NCT00764946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: raltegravir
Description: 400 mg tablets taken twice daily. Total treatment period is 48 weeks.
Study: NCT03388086

Intervention type: DRUG
Intervention: Injection of Onabotulinum toxin
Description: multiple injections of Onabotulinum toxin into the detrusor muscle

Intervention type: DRUG
Intervention: Injection of Onabotulinum toxin
Description: multiple injections of Onabotulinum toxin into the detrusor muscle
Study: NCT03675113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise
Description: Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department.
Study: NCT03552627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Medical Oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Medical Oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Medical Oxygen
Study: NCT03675113

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Deep breathing exercises combinated with arm movements
Study: NCT02588157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC X-Blade
Description: McGrath MAC X-Blade videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC X-Blade
Description: McGrath MAC X-Blade videolaryngoscope